 |
市场调查报告书
商品编码
1791926
干癣市场:KOL的洞察KOL Insight - Psoriasis |
||||||
本报告探讨了银屑病治疗领域的发展趋势，重点关注Skylizy、Tremfya和Bimzelx等领先生物製剂的临床和市场影响，预计这些药物将在未来五年内主导银屑病治疗领域。报告也分析了伊曲库宁对口服治疗领域的影响，尤其是其对奥特兹拉（Otezla）市场定位的影响，并评估了阿达木单抗和优特克单抗等生物相似药在关节炎和斑块状干癣一线治疗中日益重要的作用。报告深入探讨了不断变化的处方模式、早期生物製剂应用的推动因素，以及这些发展对未来治疗策略和市场动态的影响。
关键问题
- 目前核准的干癣药物是如何被临床医师使用和认知的？
- 已上市药物及在研药物在疗效、安全性和给药有何比较？
- 哪些药物类别预计将对未来干癣处方趋势产生最大影响？
- 生物相似药将如何影响干癣治疗模式和病患管理？
- 哪些在研产品最有可能改变目前的市场格局？
- 哪些正在进行或即将进行的临床试验有可能显着影响干癣治疗策略？
- 治疗格局将如何演变？患者群体和治疗线将如何演变？
- 新型口服药物在干癣管理中的预期作用和表现如何？
- 干癣市场中关键意见领袖 (KOL) 的期望和未满足的需求是什么？
- 新型疗法的推出将如何影响目前的治疗方案和关键参与者？
领导品牌
|
|
|
部分参加专家名单
- 加州大学洛杉矶分校大卫‧格芬医学院皮肤科临床助理教授。
- 耶鲁大学医学院皮肤病学副教授兼干癣治疗计画主任。
- 加州大学洛杉矶分校皮肤病学首席教授。
- 法国巴黎圣路易医院皮肤科教授。
- 西班牙巴塞隆纳圣克鲁斯-圣保罗医院皮肤科主任。
- 瑞士洛桑大学医院皮肤科教授。
研究方法：
"治疗趋势" 报告透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，探讨关键疾病领域的当前和未来治疗前景。 KOL 的遴选是基于严格的标准，包括全球知名度、临床专业知识以及在其治疗领域的影响力。每次访谈均配有精心编写的讨论指南。这些指南由我们与 KOL 合作制定，并由行业专家进行同行评审，以确保问题全面且与当前市场动态相关。每份报告发布后，我们都会持续进行12个月的市场监测，以便及时更新 KOL 对重要新闻事件、市场变化和市场发展的最新动态。
报告特色
FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入可行的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助客户掌握新兴趋势，有效应对复杂课题。凭藉广泛的研究以及来自顶尖专家和关键意见领袖 (KOL) 的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家访谈和数据，以及持续的市场监测，确保您能够全面了解市场动态。我们的报告涵盖 40 多个活跃的疾病领域，包括 KOL 洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售和行销、市场准入等领域问题的看法，帮助您做出更明智的数据驱动决策，并在快速变化的行业中保持竞争力。
This report examines the evolving landscape of psoriasis treatment, with a focus on the clinical and market impact of leading biologics-including Skyrizi, Tremfya, and Bimzelx-which are projected to dominate the therapeutic pathway over the next five years. It analyses the anticipated influence of icotrokinra on the oral therapy segment, particularly its effect on Otezla's positioning, and evaluates the expanding role of biosimilars such as adalimumab and ustekinumab in first-line management for joint and plaque psoriasis. Gain insights into shifting prescribing patterns, the drivers behind earlier biologic use, and the implications of these developments for future treatment strategies and market dynamics.
Key Questions Answered:
- How are currently approved therapies for psoriasis used and perceived by clinicians?
- How do marketed therapies compare with pipeline treatments in efficacy, safety, and administration?
- Which drug classes are expected to most influence future prescribing trends in psoriasis?
- What impact will biosimilars have on the psoriasis treatment paradigm and patient management?
- Which pipeline products show the most promise for changing the current market landscape?
- Which ongoing or upcoming clinical trials could significantly affect psoriasis treatment strategies?
- How will the treatment landscape evolve for different patient segments and lines of therapy?
- What is the expected role and performance of new oral therapies in psoriasis management?
- What are KOLs' expectations and unmet needs in the psoriasis market?
- How will the introduction of new therapies affect current treatment algorithms and key players?
Key Brands:
|
|
|
Partial List of Participating Experts:
- Clinical Assistant Professor of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- Assistant Professor of Dermatology; Director, Psoriasis Treatment Program, Department of Dermatology, Yale School of Medicine, New Haven, CT.
- Professor and Chief of Dermatology, University of California Los Angeles, Los Angeles, CA.
- Professor of Dermatology at Hopital Saint-Louis, Paris, France.
- Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Professor of Dermatology, Lausanne University Hospital, Lausanne, Switzerland.
Methodology:
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
